See more : DRB Holding Co., Ltd. (004840.KS) Income Statement Analysis – Financial Results
Complete financial analysis of PerkinElmer, Inc. (PKI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PerkinElmer, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- MNRB Holdings Berhad (MNRB.KL) Income Statement Analysis – Financial Results
- Zhangjiagang Furui Special Equipment Co., Ltd. (300228.SZ) Income Statement Analysis – Financial Results
- Numinus Wellness Inc. (NUMIF) Income Statement Analysis – Financial Results
- Scope Carbon Corp. (SCPE.CN) Income Statement Analysis – Financial Results
- Mr D.I.Y. Group (M) Berhad (5296.KL) Income Statement Analysis – Financial Results
PerkinElmer, Inc. (PKI)
About PerkinElmer, Inc.
PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.31B | 5.07B | 3.78B | 2.88B | 2.78B | 2.26B | 2.12B | 2.26B | 2.24B | 2.17B | 2.12B | 1.92B | 1.70B | 1.81B | 1.94B | 1.79B | 1.55B | 1.47B | 1.69B | 1.54B | 1.50B | 1.33B | 1.70B | 1.36B | 1.41B | 1.46B | 1.43B | 1.42B | 1.33B | 2.70B | 2.79B | 2.69B | 2.47B | 1.65B | 1.41B | 1.24B | 1.15B | 1.16B |
| Cost of Revenue | 1.32B | 2.22B | 1.67B | 1.49B | 1.44B | 1.18B | 1.10B | 1.24B | 1.23B | 1.19B | 1.15B | 1.07B | 945.72M | 1.03B | 1.11B | 1.06B | 918.29M | 859.30M | 1.01B | 906.27M | 904.10M | 721.73M | 918.43M | 787.30M | 991.30M | 1.04B | 1.01B | 1.01B | 957.80M | 2.30B | 2.39B | 2.31B | 2.14B | 1.35B | 1.11B | 984.00M | 935.30M | 927.90M |
| Gross Profit | 1.99B | 2.85B | 2.11B | 1.40B | 1.34B | 1.07B | 1.01B | 1.02B | 1.00B | 976.97M | 963.21M | 850.58M | 758.63M | 779.79M | 830.11M | 724.74M | 628.07M | 614.54M | 680.55M | 628.95M | 600.88M | 608.33M | 776.84M | 575.80M | 416.60M | 420.70M | 419.50M | 407.00M | 374.80M | 393.20M | 401.50M | 382.00M | 333.50M | 303.80M | 292.00M | 251.90M | 209.80M | 227.20M |
| Gross Profit Ratio | 60.08% | 56.27% | 55.78% | 48.41% | 48.27% | 47.54% | 47.90% | 45.28% | 44.90% | 45.10% | 45.54% | 44.27% | 44.51% | 43.03% | 42.84% | 40.55% | 40.62% | 41.70% | 40.34% | 40.97% | 39.93% | 45.74% | 45.82% | 42.24% | 29.59% | 28.80% | 29.39% | 28.67% | 28.13% | 14.57% | 14.40% | 14.21% | 13.48% | 18.41% | 20.76% | 20.38% | 18.32% | 19.67% |
| Research & Development | 221.62M | 274.97M | 205.39M | 189.34M | 194.00M | 139.40M | 124.28M | 125.93M | 121.14M | 133.02M | 132.64M | 115.82M | 95.41M | 107.25M | 108.06M | 111.62M | 99.72M | 87.37M | 87.05M | 83.15M | 86.45M | 81.32M | 86.12M | 71.20M | 46.00M | 44.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.03B | 1.23B | 917.89M | 815.32M | 811.91M | 616.17M | 600.89M | 598.85M | 659.34M | 585.85M | 632.73M | 628.60M | 490.66M | 504.70M | 522.88M | 444.41M | 376.85M | 365.46M | 387.54M | 386.40M | 431.30M | 411.15M | 418.98M | 327.10M | 226.30M | 243.40M | 290.90M | 284.90M | 278.20M | 234.60M | 242.00M | 223.10M | 195.90M | 179.90M | 169.30M | 151.40M | 133.20M | 130.10M |
| Other Expenses | 25.26M | 36.41M | -23.52M | -27.69M | -13.21M | 33.59M | -3.73M | -4.80M | -5.54M | -14.84M | -2.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.25B | 1.50B | 1.12B | 1.00B | 1.01B | 755.57M | 725.16M | 724.78M | 780.48M | 718.87M | 765.37M | 744.42M | 586.07M | 611.95M | 630.95M | 540.69M | 478.31M | 451.33M | 503.48M | 495.22M | 540.87M | 492.46M | 592.81M | 464.40M | 322.70M | 332.90M | 331.80M | 324.30M | 315.00M | 272.40M | 278.30M | 256.80M | 225.80M | 205.40M | 193.90M | 172.60M | 149.60M | 145.20M |
| Cost & Expenses | 2.57B | 3.72B | 2.80B | 2.49B | 2.44B | 1.94B | 1.83B | 1.96B | 2.01B | 1.91B | 1.92B | 1.82B | 1.53B | 1.64B | 1.74B | 1.60B | 1.40B | 1.31B | 1.51B | 1.40B | 1.44B | 1.21B | 1.51B | 1.25B | 1.31B | 1.37B | 1.34B | 1.34B | 1.27B | 2.58B | 2.67B | 2.56B | 2.37B | 1.55B | 1.31B | 1.16B | 1.08B | 1.07B |
| Interest Income | 3.59M | 2.24M | 1.01M | 1.50M | 1.14M | 2.57M | 702.00K | 673.00K | 667.00K | 650.00K | 747.00K | 1.88M | 832.00K | 1.04M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 103.96M | 102.13M | 49.71M | 63.63M | 66.98M | 43.94M | 41.53M | 38.00M | 36.27M | 49.92M | 45.79M | 24.78M | 15.89M | 17.16M | 16.88M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 455.85M | 413.09M | 232.02M | 217.26M | 179.66M | 105.00M | 99.97M | 112.01M | 116.74M | 128.47M | 126.87M | 110.92M | 89.16M | 91.84M | 88.31M | 80.83M | 69.48M | 124.38M | 84.34M | 89.78M | 96.11M | 84.26M | 87.72M | 66.10M | 50.40M | 44.60M | 40.90M | 39.40M | 36.80M | 37.80M | 36.30M | 33.70M | 29.90M | 25.50M | 24.60M | 21.20M | 16.40M | 15.10M |
| EBITDA | 1.20B | 1.75B | 1.21B | 579.23M | 503.55M | 458.62M | 385.13M | 407.61M | 336.00M | 372.39M | 322.53M | 218.97M | 262.56M | 260.72M | 318.07M | 168.17M | 153.40M | 358.67M | 177.07M | 137.27M | 219.48M | 281.84M | 311.28M | 243.90M | 82.10M | 166.20M | 135.90M | 118.70M | 168.00M | 151.30M | 154.30M | 154.90M | 127.60M | 113.40M | 115.80M | 91.50M | 57.20M | 79.00M |
| EBITDA Ratio | 36.19% | 34.45% | 32.00% | 20.09% | 18.13% | 20.32% | 18.21% | 18.02% | 15.02% | 17.19% | 15.25% | 11.40% | 15.41% | 14.39% | 16.42% | 15.20% | 14.24% | 24.34% | 15.80% | 17.83% | 14.58% | 21.19% | 18.36% | 17.89% | 5.83% | 11.38% | 9.52% | 8.36% | 12.61% | 5.61% | 5.53% | 5.76% | 5.16% | 6.87% | 8.23% | 7.40% | 5.00% | 6.84% |
| Operating Income | 742.70M | 1.33B | 978.58M | 361.97M | 323.88M | 304.80M | 283.07M | 286.13M | 210.74M | 217.44M | 98.54M | 89.70M | 153.60M | 147.61M | 192.97M | 168.17M | 153.40M | 140.95M | 177.07M | 137.27M | 24.32M | 37.33M | 184.03M | 111.40M | 93.90M | 87.80M | 87.70M | 82.70M | 59.80M | 120.80M | 123.20M | 125.20M | 107.70M | 98.40M | 98.10M | 79.30M | 60.20M | 82.00M |
| Operating Income Ratio | 22.43% | 26.29% | 25.87% | 12.55% | 11.66% | 13.50% | 13.38% | 12.65% | 9.42% | 10.04% | 4.66% | 4.67% | 9.01% | 8.15% | 9.96% | 9.41% | 9.92% | 9.56% | 10.49% | 8.94% | 1.62% | 2.81% | 10.86% | 8.17% | 6.67% | 6.01% | 6.14% | 5.83% | 4.49% | 4.48% | 4.42% | 4.66% | 4.35% | 5.96% | 6.98% | 6.42% | 5.26% | 7.10% |
| Total Other Income/Expenses | -90.86M | -52.49M | -72.22M | -124.83M | -66.20M | -8.09M | -39.00M | -42.12M | -41.14M | -64.11M | -47.96M | -26.77M | 8.38M | -16.94M | -45.61M | -16.88M | -2.67M | -41.61M | -40.32M | -56.39M | -32.87M | -3.18M | -39.54M | -66.50M | 62.10M | -33.80M | -7.30M | 3.40M | -76.90M | 1.10M | -2.10M | -4.90M | -500.00K | 1.40M | -700.00K | 1.70M | 12.10M | 6.60M |
| Income Before Tax | 651.84M | 1.28B | 906.36M | 237.14M | 257.68M | 296.72M | 244.07M | 244.02M | 169.60M | 153.33M | 50.59M | 62.93M | 161.98M | 130.68M | 147.36M | 151.29M | 150.74M | 66.66M | 136.75M | 80.88M | -8.55M | 34.15M | 144.49M | 44.90M | 156.00M | 54.00M | 80.40M | 86.10M | -17.10M | 121.90M | 121.10M | 120.30M | 107.20M | 99.80M | 97.40M | 81.00M | 72.30M | 88.60M |
| Income Before Tax Ratio | 19.68% | 25.26% | 23.96% | 8.22% | 9.28% | 13.15% | 11.54% | 10.79% | 7.58% | 7.08% | 2.39% | 3.28% | 9.50% | 7.21% | 7.61% | 8.46% | 9.75% | 4.52% | 8.10% | 5.27% | -0.57% | 2.57% | 8.52% | 3.29% | 11.08% | 3.70% | 5.63% | 6.07% | -1.28% | 4.52% | 4.34% | 4.47% | 4.33% | 6.05% | 6.93% | 6.55% | 6.31% | 7.67% |
| Income Tax Expense | 129.16M | 347.60M | 178.27M | 9.39M | 20.21M | 139.83M | 28.36M | 31.33M | 8.44M | -12.19M | -17.85M | 62.75M | 26.06M | 37.93M | 21.22M | 17.46M | 32.41M | 128.00K | 38.50M | 25.87M | -4.42M | 34.77M | 58.42M | 16.50M | 54.00M | 23.40M | 25.90M | 31.80M | 15.00M | 42.30M | 33.30M | 39.10M | 33.20M | 29.90M | 28.70M | 25.50M | 27.40M | 32.90M |
| Net Income | 579.18M | 932.16M | 727.89M | 227.56M | 237.93M | 292.63M | 234.30M | 212.43M | 157.78M | 164.81M | 69.94M | 6.66M | 383.92M | 85.60M | 126.41M | 131.69M | 119.58M | 268.11M | 96.04M | 52.96M | -151.94M | 34.51M | 90.52M | 154.30M | 102.00M | 33.60M | 60.20M | 68.00M | -5.60M | 59.10M | 87.80M | 81.20M | 74.00M | 69.90M | 68.70M | 55.50M | 44.90M | 55.70M |
| Net Income Ratio | 17.49% | 18.40% | 19.24% | 7.89% | 8.56% | 12.97% | 11.08% | 9.39% | 7.05% | 7.61% | 3.31% | 0.35% | 22.53% | 4.72% | 6.52% | 7.37% | 7.73% | 18.19% | 5.69% | 3.45% | -10.10% | 2.59% | 5.34% | 11.32% | 7.24% | 2.30% | 4.22% | 4.79% | -0.42% | 2.19% | 3.15% | 3.02% | 2.99% | 4.24% | 4.89% | 4.49% | 3.92% | 4.82% |
| EPS | 4.59 | 8.12 | 6.52 | 2.06 | 2.13 | 2.67 | 2.14 | 1.89 | 1.40 | 1.49 | 0.61 | 0.07 | 3.34 | 0.74 | 1.07 | 1.11 | 0.96 | 2.07 | 0.75 | 0.42 | -1.21 | 0.33 | 0.92 | 1.69 | 1.13 | 0.37 | 0.64 | 0.66 | -0.05 | 0.53 | 0.78 | 0.73 | 0.65 | 0.60 | 0.57 | 0.50 | 0.42 | 0.52 |
| EPS Diluted | 4.58 | 8.08 | 6.49 | 2.04 | 2.13 | 2.64 | 2.12 | 1.87 | 1.39 | 1.47 | 0.61 | 0.07 | 3.31 | 0.73 | 1.07 | 1.09 | 0.95 | 2.04 | 0.74 | 0.41 | -1.21 | 0.32 | 0.89 | 0.29 | 1.11 | 0.37 | 0.64 | 0.66 | -0.05 | 0.53 | 0.78 | 0.73 | 0.65 | 0.60 | 0.57 | 0.50 | 0.42 | 0.52 |
| Weighted Avg Shares Out | 126.16M | 116.17M | 111.51M | 110.83M | 110.56M | 109.86M | 109.48M | 112.51M | 112.59M | 112.25M | 113.73M | 112.98M | 117.11M | 116.25M | 117.66M | 118.64M | 124.57M | 129.52M | 128.06M | 126.09M | 125.57M | 104.56M | 98.39M | 91.30M | 90.27M | 91.08M | 94.80M | 103.03M | 112.00M | 112.57M | 112.56M | 111.23M | 113.85M | 116.50M | 119.48M | 111.00M | 108.19M | 107.12M |
| Weighted Avg Shares Out (Dil) | 126.43M | 116.67M | 112.09M | 111.50M | 111.53M | 110.86M | 110.31M | 113.32M | 113.74M | 113.50M | 114.86M | 113.86M | 117.98M | 116.59M | 118.69M | 120.81M | 125.88M | 131.43M | 129.79M | 129.17M | 125.57M | 107.83M | 101.71M | 91.30M | 91.89M | 91.08M | 94.80M | 105.98M | 112.00M | 112.57M | 112.56M | 111.23M | 113.85M | 116.50M | 119.48M | 111.00M | 108.19M | 107.12M |
WISeKey PKI and SEALSQ Post-Quantum Technologies Enhance E-Voting Security through Advanced Cybersecurity and AI Integration
WISeKey PKI and SEALSQ Post-Quantum Technologies Enhance E-Voting Security through Advanced Cybersecurity and AI Integration
Climb Channel Solutions Announces Keyfactor as New North American Channel Partner
Partnership will expand reach of best-in-class PKI and certificate solutions throughout North America Partnership will expand reach of best-in-class PKI and certificate solutions throughout North America
PARKLAND ANNOUNCES PRICING OF SENIOR UNSECURED NOTES OFFERING
CALGARY, AB , Aug. 12, 2024 /PRNewswire/ - Parkland Corporation ("Parkland", "we", the "Company", or "our") (TSX: PKI) announced today that it has priced its previously announced private offering of US$500 million of senior unsecured notes due 2032 at an...
PARKLAND ANNOUNCES US$500 MILLION OFFERING OF SENIOR UNSECURED NOTES
CALGARY, AB , Aug. 12, 2024 /PRNewswire/ - Parkland Corporation ("Parkland", "we", the "Company", or "our") (TSX: PKI) announced today that, subject to market and other conditions, it plans to commence a private offering of US$500 million aggregate principal amount...
PerkinElmer Acquires Covaris to Create an Innovation-Led, Global Life-Sciences and Diagnostics Platform
SHELTON, Conn.--(BUSINESS WIRE)--PerkinElmer, a leading global analytical services and solutions provider, today announced that it has acquired Covaris, a leading developer of solutions to empower life science innovations. The merger will accelerate Covaris' growth potential and expand PerkinElmer's existing life...
Parkland appoints Nora Duke to its Board of Directors
CALGARY, AB, July 14, 2023 /PRNewswire/ – Parkland Corporation (“Parkland”, “we”, the “Company”, or “our”) (TSX: PKI) today announced the appointment of Nora Duke to Parkland’s Board of Directors (the “Board”), effective today. “We are delighted to welcome Nora to...
PerkinElmer (PKI) Q1 Earnings Surpass Estimates
PerkinElmer (PKI) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.99 per share. This compares to earnings of $2.41 per share a year ago.
Revvity Announces Financial Results for the First Quarter of 2023
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: PKI), today reported financial results for the first quarter ended April 2, 2023. The Company reported GAAP earnings per share of $4.50, as compared to $1.40 in the same period a year ago. GAAP revenue...
Is a Surprise Coming for Revvity (PKI) This Earnings Season?
Revvity (PKI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Revvity (PKI) to Report Q1 Earnings: Is a Beat in the Cards?
Revvity's (PKI) first-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for Life Sciences and Diagnostics franchise.
Source: https://incomestatements.info
Category: Stock Reports